Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | LIPE | Q05469 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27138377 | 0.82 | LIPE (0.35) | USP30LIPEUCHL1 | |
| SCHEMBL27136595 | 0.81 | UCHL1 (0.36) | USP30LIPEUCHL1 | |
| SCHEMBL24665097 | 0.81 | USP30 (0.32) | USP30ABL1LIPEUCHL1 | |
| SCHEMBL19744093 | 0.81 | SIRT6 (0.37) | USP30LIPEUCHL1 | |
| SCHEMBL29653311 | 0.78 | LIPE (0.40) | LIPEUCHL1 | |
| SCHEMBL17863621 | 0.78 | LIPE (0.33) | USP30LIPEUCHL1 | |
| SCHEMBL9943204 | 0.78 | LIPE (0.40) | LIPEUCHL1 | |
| SCHEMBL17841659 | 0.77 | CNR1 (0.42) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27139969 | 0.76 | GSK3A (0.40) | LIPERAB9ASMN1; SMN2UCHL1 | |
| SCHEMBL24667122 | 0.75 | UCHL1 (0.36) | USP30LIPEUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577546-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | Enliven Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044713-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-02-29 | — | — | WO | disclosed |